ORAGENICS INC
Close on Oct 19, 2026
- Market cap
- $1.87M
- P/E (TTM)
- –
- Dividend yield
- –
About Oragenics
Pharmaceutical Preparations, SIC 2834
Oragenics, Inc. is a development-stage biopharmaceutical company focused on the research and development of nasal delivery therapies for neurological conditions and infectious diseases. The company concentrates on advancing its lead product candidate, ONP-002, a synthetic neurosteroid engineered to cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation. Administered through a lightweight, breath-propelled intranasal powder device, the drug candidate targets mild traumatic brain injury, commonly referred to as concussion. As an investigational biopharmaceutical business without commercialized products, the enterprise aims to pursue future distribution and licensing partnerships with industry collaborators and qualified distributors.
The company operates from its principal executive offices in Lakewood Ranch, Florida. It holds patents and pending applications across the United States, Canada, the Philippines, and several European jurisdictions, and conducts clinical testing operations in Australia. Oragenics currently has no products cleared or authorized for commercial distribution across the United States, Europe, or other international territories.
Summary of the business section of Oragenics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ORAGENICS INC
- Headquarters
- Lakewood Ranch, FL
- Address
- 9015 Town Center Parkway, Suite 143 34202
- Phone
- (813) 286-7900
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Florida
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- OGEN
- Exchange
- NYSE
- Shares outstanding
- 5M, Aug 12, 2026
- Public float
- $3.13M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Jun 3, 2025; 1-for-58 reverse, Apr 17, 2023; 1-for-60 reverse, Jan 23, 2023; 1-for-10 reverse, Jan 22, 2018; 1-for-10 reverse, Jan 8, 2018; 1-for-20 reverse, Sep 28, 2010
- SEC CIK
- 1174940
- CUSIP
- 684023609
- ISIN
- US6840236094
- LEI
- 549300639MGD19K4ZW90
- EIN
- 59-3410522
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Spencer | Chief Financial Officer | 53 |
| Janet Huffman | CEO and CFO | 15,000 |
| Fred Telling | Director | 948 |
| Charles L. Pope | Director | 25,471 |
| Natasha Giordano | Director | – |
| John P. Gandolfo | Director | – |
| Alan W. Dunton | Director | 25,623 |
| Robert C. Koski | Director | 51,307 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $609.16K | $407.46K | $609.16K | $1 | – |
| FY2024 | $745.07K | $279.70K | $275.95K | $-18 | – |
| FY2024 Michael Redmond | $464.14K | $115.11K | $275.95K | $-18 | – |
| FY2024 Non Peo Neo | $322.31K | $275.04K | $275.95K | $-18 | – |
| FY2023 Kimberly Murphy | $592.15K | $180.48K | $140.12K | $14 | – |
| FY2023 Michael Redmond | $592.15K | $517.24K | $140.12K | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had three full-time and part-time employees.”
Corporate history
Events identified from SEC filings